We found hotspot mutations with a VAF >10% in the normal samples in 6 AML cases with DNMT3A p.R882X, 5 with IDH2 p.R140Q, 3 with JAK2 p.V617F and 1 with TP53 p.R273X, IDH2 p.R172K and NRAS p.Q61X, and in 4 MPN cases with JAK2 p.V617F. This evidence concerns the gene DNMT3A and myeloproliferative neoplasm.